Clinical efficacy of gemcitabine combined with oxaliplatin on advanced platinum resistant ovarian cancer

Abstract

Objective To investigate the clinical efficacy of gemcitabine combined with oxaliplatin (GEMOX) on platinum resistant epithelial ovarian cancer. Methods A total of 45 recurrent epithelial ovarian cancer patients were selected.All the patients were treated with gemcitabine(850 mg/m2) on the first and eight day, and oxaliplatin (100 mg/m2) on the first day, three weeks as a therapeutic cyclic, 2-4 therapeutic cycles were performed. The clinical efficacy and adverse reactions were recorded. Results Among the 45 cases, 3 cases of complete remission, 13 cases of partial remission, 20 cases of stable disease, 9 cases of progression of disease. The objective response rate was 35.6%, and the disease control rate was 80.0%. The dose-limiting toxicities were anemia, thrombocytopenia, nausea/nomiting, which were moderate and manageable. Conclusions Gemcitabine combined with oxaliplatin showes obvious clinical efficacy in the treatment of advanced recurrent epithelial ovarian cancer with tolerable adveres effects. Key words: Ovarian cancer; Drug therapy; Platinum resistant